Arbutus expects to significantly reduce its net cash burn in 2025

Arbutus Biopharma (NASDAQ:ABUS) announced on Monday its 2025 corporate objectives and provided a financial update. The company had cash, cash equivalents and investments in marketable securities totaling approximately $123 million as of December 31, 2024.

The company expects to significantly